- Home
- ZD vs RLAY Comparison
ZD vs RLAY Comparison
Compare ZD & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZD | RLAY |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 1999 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ZD | RLAY |
|---|---|---|
| Price | $27.66 | $9.98 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $36.50 | $14.50 |
| AVG Volume (30 Days) | 746.5K | ★ 2.2M |
| Earning Date | 05-27-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.78 |
| EPS | ★ 1.15 | N/A |
| Revenue | ★ $1,364,028,000.00 | $15,355,000.00 |
| Revenue This Year | $6.73 | N/A |
| Revenue Next Year | $3.36 | $178.50 |
| P/E Ratio | $23.43 | ★ N/A |
| Revenue Growth | N/A | ★ 53.44 |
| 52 Week Low | $22.45 | $1.78 |
| 52 Week High | $43.54 | $11.43 |
Technical Indicators
Market Signals| Indicator | ZD | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 36.00 | 62.75 |
| Support Level | N/A | $7.22 |
| Resistance Level | $33.47 | N/A |
| Average True Range (ATR) | 1.90 | 0.67 |
| MACD | -0.33 | 0.09 |
| Stochastic Oscillator | 48.39 | 48.61 |
Price Performance
Historical ComparisonAbout ZD Ziff Davis Inc.
Ziff Davis Inc is a focused digital media and internet company whose portfolio includes brands in technology, entertainment, shopping, health, cybersecurity, and martech. It has two reportable segments: Digital Media and Cybersecurity and Martech. The company's brands include Mashable, Ookla, Offers.com, IGN, and VPN among others. The majority of revenue is generated from Digital Media.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).